The Most Prominent Updates in Biosimilars Discussed by Merck, Lupin, IMS Health and European Regulatory Agencies

Just three weeks remain until the medical industry gathers for SMi’s established Biosismilars Europe show which will return to Central London on 29th and 30th September for its 7th annual show.

Programme highlights will include:

• Discussions on critical developments in market access, commercialisation, p&r and the next decade of biosimilar drug development.
• Updates in European, UK and US regulation.
• A comparison on the correlation between biosimilars market share and price erosion of biosimilars medicine.
• Case study insight on switching experiences and clinical trials.
• Presentations covering translational challenges with incorporating biosimilars into
healthcare.
• Progressive outlook on new opportunities in emerging markets.
• A comparative and functional study between innovator and originator.
• Insight into the next generation of medical device components to differentatate biosimilars.

Duncan Emerton from pharmaceutical intelligence providers, FirstWord, who will be opening the conference said:

"I'm always looking to learn new insights and perspectives on the biosimilars market. Meeting new people, expanding my network and listening to where other people believe the market is headed is also something I hope to gain from the meeting"

A snapshot of those who have already confirmed attendance include:

3SBio Pharmaceutical Group, Anteris Medical GmbH, Austrian Agency for Health and Food Safety, Ayva Pharma, Boehringer Ingelheim, Bristows LLC, Daiichi Sankyo, F. Hoffmann-La Roche, FirstWord, Genmab, Health Products Regulatory Authority, IMS Health UK, Libbs FarmacÛutica, Louise Leong ABPI, Lupin Limited, mAbxience, medac GmbH, Merck Group, Mylan BGP Pharma Hellas , Napp Pharmaceuticals, Norwegian Medicines Agency, Orygen Biotecnoloiga, Pharma Circle, RJW & Partners, SAI MedPartners, Sandoz International, Sanofi-Aventis, Sartorius Stedim BioOutsource, Schwegman Lundberg Woessner + more.

Further information is available online at http://www.biosimilars-europe.com/openpr

Biosimilars Europe
29th & 30th September 2016
Holiday Inn Kensington Forum, London UK
Sponsored by: Abzena and Schwegman Lundberg Woessner

---end ---

Contact information:

For media enquires contact Teri Arri on +44 (0)20 7827 6162 or email tarri@smi-online.co.uk
To sponsor the event, contact Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk
To contact the sales team, call Fateja Begum on +44 (0)20 7827 6184 or email fbegum@smi-online.co.uk

About SMi:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

2 Floor Harling House
47-51 Great Suffolk Street

This release was published on openPR.